Management of myelofibrosis after ruxolitinib failure
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04002-9
Abstract: Myelofibrosis is a BCR-ABL1–negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, constitutional symptoms, leukemic progression, and shortened survival. Constitutive activation of the Janus kinase/signal transducers and activators of transcription (JAK-STAT)… read more here.
Keywords: ruxolitinib failure; fedratinib; ruxolitinib; myelofibrosis ruxolitinib ... See more keywords